Výsledky vyhledávání - "达沙替尼"

[Dasatinib combined with multi-agent chemotherapy regimen in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a prospective study from a single center]

Autor: G J, Zhang, X Y, Gong, S W, Qiu, C L, Zhou, K Q, Liu, D, Lin, B C, Liu, H, Wei, S N, Wei, Y, Li, R X, Gu, B F, Gong, Y T, Liu, Q Y, Fang, Y C, Mi, Y, Wang, J X, Wang

Publikováno v: Chinese Journal of Hematology

目的评价达沙替尼联合多药化疗方案在Ph染色体阳性急性淋巴细胞白血病（Ph+ ALL）患者中的疗效及安全性。方法前瞻性、单臂、开放的临床研究。2016年1月至2018年4月中国医学科学院血液病

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e50bdb35ead291e066451cb89be1554d
https://pubmed.ncbi.nlm.nih.gov/33858040

Zobrazit plný text záznamu

Autor: S, Yang, Y Z, Qin, Y Y, Lai, H X, Shi, Y, Hou, X J, Huang, Q, Jiang

Publikováno v: Chinese Journal of Hematology

目的探索慢性髓性白血病（CML）患者接受达沙替尼治疗中肺部不良反应的发生率、影响因素及治疗转归。方法回顾性分析2008年4月至2020年1月在北京大学人民医院接受达沙替尼治疗的CML患者

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::24d41b3c864d9aaf555604bf5ae7dd10
https://pubmed.ncbi.nlm.nih.gov/33445849

Zobrazit plný text záznamu

国产达沙替尼二线治疗慢性髓性白血病慢性期患者的疗效和安全性分析

Publikováno v: Chinese Journal of Hematology

目的探讨国产酪氨酸激酶抑制剂（TKI）达沙替尼（商品名：依尼舒）二线治疗慢性髓性白血病慢性期（CML-CP）患者的疗效及安全性。方法回顾性分析2016年3月至2018年7月湖北省CML协作组成员

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c3c71c0269bed89fe83b6fddd68b1b98
http://europepmc.org/articles/PMC7342660

Zobrazit plný text záznamu

[Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase]

Autor: T, Yuan, Y Y, Lai, Y Z, Qin, H X, Shi, X J, Huang, Y, Hou, Q, Jiang

Publikováno v: Chinese Journal of Hematology

目的分析二代酪氨酸激酶抑制剂（TKI）尼洛替尼和达沙替尼作为二三线药物治疗慢性髓性白血病（CML）慢性期（CP）和加速期（AP）患者的治疗反应和预后，以及相关影响因素。方法回顾性

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c354aa7af79178501ec002dff477e3d7
https://pubmed.ncbi.nlm.nih.gov/32135623

Zobrazit plný text záznamu

[Comparison of efficacy of first-line administration of generic dasatinib or imatinib in patients with Philadelphia chromosome positive acute lymphoblastic leukemia treated by hematopoietic stem cell transplantation]

Autor: F, Yang, W Z, Cai, X W, Huang, S L, Xue, C C, Fu, X W, Tang, A N, Sun, D P, Wu, H Y, Qiu

Publikováno v: Chinese Journal of Hematology

目的探讨接受造血干细胞移植的Ph染色体阳性急性淋巴细胞白血病（Ph+ALL）患者一线应用国产达沙替尼与一代酪氨酸激酶抑制剂（TKI）伊马替尼的疗效差异。方法回顾性分析2014年1月至2017�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c34114a5ebf38c8d5f4b781018ccbbd4
https://pubmed.ncbi.nlm.nih.gov/30180468

Zobrazit plný text záznamu

国产达沙替尼治疗慢性髓性白血病慢性期患者的药代动力学研究

Publikováno v: Chinese Journal of Hematology

目的探讨国产达沙替尼在慢性髓性白血病慢性期（CML-CP）患者的药代动力学特征及与原研达沙替尼制剂的生物等效性比较。方法采用随机、平行、交叉、自身对照设计进行试验。12例对甲�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a1f3d5dc947800fae78f187fd0637a5a
http://europepmc.org/articles/PMC7348510

Zobrazit plný text záznamu

[Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia]

Autor: Qian, Jiang, Yazhen, Qin, Yueyun, Lai, Hao, Jiang, Hongxia, Shi

Publikováno v: Chinese Journal of Hematology

To evaluate the efficiency of dasatinib as the second- or third-line tyrosine kinase inhibitor (TKI)in imatinib-resistant patients with chronic myeloid leukemia (CML)based on BCR-ABL mutation detection.122 CML patients received dasatinib treatment, i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4506a41aaf2d892f90fd9f92973d7da9
https://pubmed.ncbi.nlm.nih.gov/26876246

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání